Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026
Rhea-AI Summary
Elutia (NASDAQ: ELUT) will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Management will host a conference call and webcast the same day at 5:00 p.m. ET / 2:00 p.m. PT.
A live and archived webcast will be available in the Investors section at http://investors.elutia.com/. Registered participants receive dial-in details and a PIN, and the system can dial out when the call begins.
Positive
- None.
Negative
- None.
News Market Reaction – ELUT
In the Feb 26 session, ELUT gained 5.50%, reflecting a notable positive market reaction. Argus tracked a trough of -8.8% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Workplace recognition | Positive | +4.3% | Great Place to Work 2026 certification and culture highlights. |
| Jan 12 | Prelim Q4 results | Positive | -4.8% | Preliminary Q4 2025 results, asset-sale proceeds, and NXT-41x milestones. |
| Jan 09 | Conference presentation | Positive | +4.7% | NXT-41x program presentation at Global BioInnovation Forum. |
| Nov 06 | Q3 earnings & sale | Positive | -5.0% | Q3 2025 results and $88M BioEnvelope sale to Boston Scientific. |
| Oct 23 | Earnings date set | Neutral | -0.7% | Announcement of Q3 2025 earnings release date and conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news with operational or program updates often produced larger moves, while earnings-related releases, including preliminary results, have sometimes seen negative reactions despite seemingly constructive content.
Over the past few months, Elutia has combined financial updates with strategic repositioning and NXT-41x development. Q3 and preliminary Q4 2025 earnings news included asset-sale proceeds and debt reduction but saw -5% and -4.76% moves. By contrast, culture recognition and NXT-41x presentations on Feb 18 and Jan 9 coincided with gains of 4.35% and 4.71%. A prior earnings-date scheduling release on Oct 23 had only a modest -0.66% reaction, suggesting today’s scheduling news fits a low-impact pattern historically.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day.
The conference call can be accessed using the following information:
Webcast: Click here
Dial-In: Click here
To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register.
Please log in approximately 10 minutes prior to the scheduled start time. A live and archived webcast of the event will be available on the “Investors” section of the Elutia website at http://investors.elutia.com/.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Elutia Investor Relations
ir@elutia.com
